Joanne Hama

Array ( [id] => 18692624 [patent_doc_number] => 20230322940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => ANTI-CD44 SINGLE-CHAIN ANTIBODY AND USE THEREOF IN PREPARING DRUG FOR TREATING TUMOR [patent_app_type] => utility [patent_app_number] => 18/018764 [patent_app_country] => US [patent_app_date] => 2021-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018764 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18208549 [patent_doc_number] => 20230054807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => NEUTRALIZING MONO-SPECIFIC IgY ANTIBODIES TO INHIBIT OR TREAT SARS-COV-2 CORONAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 17/387218 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8254 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387218 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18565720 [patent_doc_number] => 20230256047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULAR DYSTROPHY [patent_app_type] => utility [patent_app_number] => 18/010526 [patent_app_country] => US [patent_app_date] => 2021-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27292 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 90 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18010526 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18022040 [patent_doc_number] => 20220373539 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => PREDICTION OF CLINICAL RESPONSE TO IL23-ANTAGONISTS USING IL23 PATHWAY BIOMARKERS [patent_app_type] => utility [patent_app_number] => 17/328816 [patent_app_country] => US [patent_app_date] => 2021-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17328816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17274497 [patent_doc_number] => 20210380695 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-09 [patent_title] => STING AGONIST COMBINATION TREATMENTS WITH IMMUNE CHECKPOINT INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/322827 [patent_app_country] => US [patent_app_date] => 2021-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11515 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17322827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17533699 [patent_doc_number] => 20220112308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => KRAS SPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/243129 [patent_app_country] => US [patent_app_date] => 2021-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63144 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -73 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17243129 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200118 [patent_doc_number] => 20210340213 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => MODIFIED CTLA4 AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/222881 [patent_app_country] => US [patent_app_date] => 2021-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17222881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18308570 [patent_doc_number] => 20230112470 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-13 [patent_title] => USE OF EGFR/HER2 TYROSINE KINASE INHIBITORS AND/OR HER2/HER3 ANTIBODIES FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS [patent_app_type] => utility [patent_app_number] => 17/759824 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14357 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -79 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17759824 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885428 [patent_doc_number] => 20210171623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => HUMAN ANTIBODY SPECIFIC FOR INTERLEUKIN-1ALPHA [patent_app_type] => utility [patent_app_number] => 17/154137 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036738 [patent_doc_number] => 20210253696 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => BIVALENT CHIMERIC ENGULFMENT RECEPTORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/154959 [patent_app_country] => US [patent_app_date] => 2021-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21878 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17154959 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16946620 [patent_doc_number] => 20210205311 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-08 [patent_title] => Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors [patent_app_type] => utility [patent_app_number] => 17/138485 [patent_app_country] => US [patent_app_date] => 2020-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32412 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17138485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778024 [patent_doc_number] => 20210115102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => SEPARATION MOIETIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/082955 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59385 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082955 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778049 [patent_doc_number] => 20210115127 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => ANTI-IL-27 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/033469 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17033469 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929847 [patent_doc_number] => 20220324972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => IMMUNOTHERAPY COMPOUNDS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/641594 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11022 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17641594 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17913258 [patent_doc_number] => 20220315653 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => BISPECIFIC BINDING AGENT THAT BINDS TO CD117/c-KIT AND CD3 [patent_app_type] => utility [patent_app_number] => 17/640412 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12453 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17640412 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671404 [patent_doc_number] => 20210060167 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => CARBON MONOXIDE-RELEASING MOLECULE CONJUGATES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/004522 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10853 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20634432 [patent_doc_number] => 12595300 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-07 [patent_title] => Anti-human P40 protein domain antibody and use thereof [patent_app_type] => utility [patent_app_number] => 17/631797 [patent_app_country] => US [patent_app_date] => 2020-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 21 [patent_no_of_words] => 21133 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17631797 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16596707 [patent_doc_number] => 20210023238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => TRIPTOLIDE ANTIBODY CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/937483 [patent_app_country] => US [patent_app_date] => 2020-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16937483 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16762388 [patent_doc_number] => 20210107969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-15 [patent_title] => MOLECULES, COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 16/925068 [patent_app_country] => US [patent_app_date] => 2020-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 99330 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925068 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598351 [patent_doc_number] => 20210024882 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCING CELL CULTURE [patent_app_type] => utility [patent_app_number] => 16/921626 [patent_app_country] => US [patent_app_date] => 2020-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22656 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16921626 [rel_patent_id] =>[rel_patent_doc_number] =>)